Immune intervention at diagnosis - Should we treat children to preserve beta-cell function?

Pediatric Diabetes

Volumn 8, Issue SUPPL. 6, 2007, Pages 34-39

  Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; C PEPTIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIAZOXIDE; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN; INSULIN; MONOCLONAL ANTIBODY CD3; NICOTINAMIDE; PEPTIDE DERIVATIVE; PLACEBO; STEROID; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL FUNCTION; CHILD; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DRUG FEVER; DRUG MEGADOSE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LEUKOPENIA; LOW DRUG DOSE; METABOLIC BALANCE; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; ONSET AGE; PANCREAS ISLET BETA CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SIDE EFFECT; SYNDROME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VACCINATION;

AUTOANTIGENS; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; INSULIN; INSULIN-SECRETING CELLS;

EID: 34548265826     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2007.00299.x     Document Type: Review

References (30)

1. Ludvigsson J, Heding LG, Larsson Y, Leander E. C-peptidein juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 1977: 66: 177-184.
2. Ludvigsson J, Heding LG. Beta-cell function in children with diabetes. Diabetes 1978: 27 (Suppl. 1): 230-234.
3. Pozzilli P, Manfrini S, Buzzetti R et al.; IMDIAB G roup. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study. Diabetes Res Clin Pract 2005: 68: 258-264.
4. Madsbad S, Alberti KG, Binder C et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979: 2: 1257-1259.
5. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003: 26: 832-836.
6. Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide. Diabetologia 2007: 50: 503-509.
7. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989: 320: 550-554.
8. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual ß-Cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized controlled trial. Ann Intern Med 1998: 128: 517-523.
9. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993: 10: 927-928.
10. Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Prevention Trial. N Engl J Med 2002: 346: 1685-1691.
11. Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005: 28: 1068-1076.
12. Ludvigsson J, Heding L, Lieden G, Marner B, Lernmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J 1983: 286: 176-178.
13. Baekkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, Lernmark A. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 1982: 298: 167-169.
14. Heinze E. Immunoglobulins in children with autoimmune diabetes mellitus. Clin Exp Rheumatol 1996: 14 (Suppl. 15): S99-S102.
15. Dupre J, Stiller CR, Gent M et al. Clinical trials of cyclosporin in IDDM. Diabetes Care 1988: 11 (Suppl. 1): 37-44.
16. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnsson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988: 319: 599-604.
17. Coutant R, Landais P, Rosilio M et al. Low dose linomide in Type I juvenile diabetes of recent onset: A randomised placebo-controlled double blind trial. Diabetologia 1998: 41: 1040-1046.
18. Eisenbarth GS, Srikanta S, Jackson R et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985: 2: 271-276.
19. FaresjöM, Ernerudh J, Berlin G, Garcia J, Ludvigsson J. The immunological effect of photopheresis in children with newly diagnosed type 1 diabetes. Pediatr Res 2005: 58: 459-466.
20. Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: A randomised, double blind, placebo controlled trial. Arch Dis Child 2001: 85: 149-154.
21. Elliot RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991: 34: 362-365.
22. European Nicotinamide Diabetes Intervention Trial (ENDIT). A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004: 363: 925-931.
23. Ludvigsson J, Samuelsson U, Johansson C, Stenhammar L. Treatment with antioxidants at onset of type 1 diabetes in children: A randomized, double-blind placebo-controlled study. Diabetes Metab Res Rev 2001: 17: 131-136.
24. Örtqvist E, Björk E, Wallensteen M et al. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004: 27: 2191-2197.
25. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005: 352: 2598-2608.
26. Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005: 54: 1763-1769.
27. Voltarelli JC, Couri CE, Stracieri AB et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007: 297: 1568-1576.
28. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 2001: 358: 1749-1753.
29. Schloot NC, Meierhoff G, Lengyel C et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: Two prospective, randomized, double-blind phase II trials. Diabetes/Metabolism Research and Reviews 2006. Diabetes Metab Res Rev 2007: 23: 276-285.
30. Agardh C-D, Corrado MC, Lethagen ÅL et al. Clinical evidence for safety of GAD 65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005: 19: 238-246.